Combination Efficacy of Voriconazole and Amphotericin B in the Experimental Disease in Immunodeficient Mice Caused by Fluconazole-resistant Cryptococcus neoformans

Mycopathologia

Volumn 171, Issue 4, 2011, Pages 261-266

  Silva, Eriques Gonçalves ^a   Paula, Claudete Rodrigues ^a   Dias, Amanda Latercia Tranches ^b   Chang, Marilene Rodrigues ^c   Ruiz, Luciana da Silva ^a   Gambale, Valderez ^a   Prates, Renato Araujo ^d   Ribeiro, Martha Simões ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^c FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^d INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Amphotericin B; Combination therapeutic; Cryptococcus neoformans; Immunodeficient murine model; SCID; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANIMAL; ANTIFUNGAL RESISTANCE; ARTICLE; BACTERIAL COUNT; BAGG ALBINO MOUSE; BRAIN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; LUNG; METHODOLOGY; MICROBIOLOGY; MOUSE; MOUSE MUTANT; RODENT DISEASE; SURVIVAL; TREATMENT OUTCOME; YEAST;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; COLONY COUNT, MICROBIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; FLUCONAZOLE; LUNG; MICE; MICE, INBRED BALB C; MICE, SCID; PYRIMIDINES; RODENT DISEASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES; YEASTS;

ANIMALIA; CRYPTOCOCCUS NEOFORMANS VAR. GRUBII; FILOBASIDIELLA NEOFORMANS; FUNGI; MURINAE; MUS;

EID: 79953023980     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9375-5     Document Type: Article

References (27)

1. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: American Society for Microbiology; 1998.
2. Silva E, Baroni FA, Viani F, Ruiz LS, Gandra R, Auler M, Dias A, Gambale W, Paula C. Virulence profile of strains of cryptococcus neoformans var. grubii evaluated by experimental infection in balb/c mice and correlation with exoenzyme activity. J Med Microbiol. 2006; 55: 139-42.
3. Pappalardo MC, Paschoal RC, Melhem MS. Aids-associated central nervous system cryptococcosis: a brazilian case study. AIDS. 2007; 21: 1971-2.
4. Clemons KV, Azzi R, Stevens DA. Experimental systemic cryptococcosis in scid mice. J Med Vet Mycol. 1996; 34: 331-5.
5. Huffnagle GB, Yates JL, Lipscomb MF. T cell-mediated immunity in the lung: a cryptococcus neoformans pulmonary infection model using scid and athymic nude mice. Infect Immun. 1991; 59: 1423-33.
6. Graybill JR, Najvar LK, Gonzalez GM, Hernandez S, Bocanegra R. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother. 2003; 51: 1373-6.
7. Powderly WG. Cryptococcal meningitis in HIV-infected patients. Curr Infect Dis Rep. 2000; 2: 352-7.
8. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in cryptococcus neoformans cambodian isolates: April 2000-March 2002. J Antimicrob Chemother. 2004; 54: 563-5.
9. Peman J, Salavert M, Canton E, Jarque I, Roma E, Zaragoza R et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag. 2006; 2: 129-58.
10. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin b against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50: 2009-15.
11. Martinez LR, Ntiamoah P, Gacser A, Casadevall A, Nosanchuk JD. Voriconazole inhibits melanization in cryptococcus neoformans. Antimicrob Agents Chemother. 2007; 51: 4396-400.
12. van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of voriconazole on cryptococcus neoformans. Antimicrob Agents Chemother. 2004; 48: 2014-20.
13. Powers JH. Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis. 2004; 39(Suppl 4): S228-35.
14. Kurtzman CP, Fell JW. The yeasts: a taxonomic study. 4th ed. Amsterdam: Elsevier Science; 1998. 1055 p.
15. Ikeda R, Shinoda T, Fukazawa Y, Kaufman L. Antigenic characterization of cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol. 1982; 16: 22-9.
16. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility of yeasts. Approved standard M27-A3. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
17. Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D et al. Interactions between triazoles and amphotericin B against cryptococcus neoformans. Antimicrob Agents Chemother. 2000; 44: 2435-41.
18. Serena C, Pastor FJ, Marine M, Rodriguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother. 2007; 60: 162-5.
19. Mavrogiorgos N, Zaragoza O, Casadevall A, Nosanchuk JD. Efficacy of voriconazole in experimental cryptococcus neoformans infection. Mycopathologia. 2006; 162: 111-4.
20. Espinel-Ingroff A. Clinical relevance of antifungal resistance. Infect Dis Clin North Am. 1997; 11: 929-44.
21. Schwarz P, Dromer F, Lortholary O, Dannaoui E. Efficacy of amphotericin b in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother. 2006; 50: 113-20.
22. Brouwer A, Rajanuwong A, Chierakul W, Griffin G, Larsen R, White N et al. Combination antifungal therapies for hiv-associated cryptococcal meningitis: a randomised trial. Lancet. 2004; 363: 1764-7.
23. Pastor FJ, Guarro J. The role of voriconazole in the treatment of emerging mycoses. Rev Iberoam Micol. 2007; 24: 228-32.
24. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of cryptococcus gattii and cryptococcus neoformans. Antimicrob Agents Chemother. 2009; 53: 309-11.
25. Stevens DA, Kullberg BJ, Brummer E, Casadevall A, Netea MG, Sugar AM. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med Mycol. 2000; 38(Suppl 1): 305-15.
26. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM et al. Antifungal susceptibilities of clinical isolates of candida species, cryptococcus neoformans, and aspergillus species from taiwan: Surveillance of multicenter antimicrobial resistance in taiwan program data from 2003. Antimicrob Agents Chemother. 2005; 49: 512-7.
27. Friese G, Discher T, Fussle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for aids-associated cryptococcal disease. AIDS. 2001; 15: 2344-5.